BridgeBio Pharma, Inc. (BBIO): Revenue
$502.08M
Year ended 2025-12-31
$713.07M
Trailing 12 months to 2026-06-30
+86.3%
3-year compound annual growth
n/m
5-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $502.08M | +126.3% | 2026-02-24, From 2025-01-01 |
| 2024-12-31 | $221.90M | n/m | 2026-02-24, From 2024-01-01 |
| 2023-12-31 | $9.30M | -88.0% | 2026-02-24, From 2023-01-01 |
| 2022-12-31 | $77.65M | +11.4% | 2025-02-20, From 2022-01-01 |
| 2021-12-31 | $69.72M | +745.1% | 2024-02-22, From 2021-01-01 |
| 2020-12-31 | $8.25M | -79.7% | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | $40.56M | n/a | 2022-02-25, From 2019-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | $502.08M | +126.3% |
| Travere Therapeutics, Inc. (TVTX) | 2025-12-31 | $490.73M | +110.5% |
| Mirum Pharmaceuticals, Inc. (MIRM) | 2025-12-31 | $521.31M | +54.7% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $480.14M | +5.7% |
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | $548.51M | -13.0% |
| Zai Lab Ltd (ZLAB) | 2025-12-31 | $457.18M | +15.0% |
| Organogenesis Holdings Inc. (ORGO) | 2025-12-31 | $564.17M | +17.0% |
| Insmed Inc (INSM) | 2025-12-31 | $606.42M | +66.7% |
| Opko Health, Inc. (OPK) | 2025-12-31 | $606.88M | -14.9% |
Compare BBIO, TVTX, MIRM, NATR side by side · Screen every company in Pharmaceutical Preparations ↗